140 related articles for article (PubMed ID: 34323910)
1. Gene-editing by CRISPR-Cas9 in combination with anthracycline therapy via tumor microenvironment-switchable, EGFR-targeted, and nucleus-directed nanoparticles for head and neck cancer suppression.
Wang CS; Chang CH; Tzeng TY; Lin AM; Lo YL
Nanoscale Horiz; 2021 Sep; 6(9):729-743. PubMed ID: 34323910
[TBL] [Abstract][Full Text] [Related]
2. PEG-coated nanoparticles detachable in acidic microenvironments for the tumor-directed delivery of chemo- and gene therapies for head and neck cancer.
Lo YL; Chang CH; Wang CS; Yang MH; Lin AM; Hong CJ; Tseng WH
Theranostics; 2020; 10(15):6695-6714. PubMed ID: 32550898
[No Abstract] [Full Text] [Related]
3. Tumor pH-functionalized and charge-tunable nanoparticles for the nucleus/cytoplasm-directed delivery of oxaliplatin and miRNA in the treatment of head and neck cancer.
Lo YL; Lin HC; Tseng WH
Acta Biomater; 2022 Nov; 153():465-480. PubMed ID: 36115656
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of pH-Sensitive Multifunctional Lipids for Efficient Delivery of CRISPR/Cas9 in Gene Editing.
Sun D; Sun Z; Jiang H; Vaidya AM; Xin R; Ayat NR; Schilb AL; Qiao PL; Han Z; Naderi A; Lu ZR
Bioconjug Chem; 2019 Mar; 30(3):667-678. PubMed ID: 30582790
[TBL] [Abstract][Full Text] [Related]
6. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
Hong ST; Lin H; Wang CS; Chang CH; Lin AM; Yang JC; Lo YL
J Nanobiotechnology; 2019 Aug; 17(1):89. PubMed ID: 31426807
[TBL] [Abstract][Full Text] [Related]
7. A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy.
Yi K; Kong H; Zheng C; Zhuo C; Jin Y; Zhong Q; Mintz RL; Ju E; Wang H; Lv S; Lao YH; Tao Y; Li M
Biomaterials; 2023 Nov; 302():122349. PubMed ID: 37844429
[TBL] [Abstract][Full Text] [Related]
8. Identifying Signalling Pathways Regulated by GPRC5B in β-Cells by CRISPR-Cas9-Mediated Genome Editing.
Atanes P; Ruz-Maldonado I; Hawkes R; Liu B; Persaud SJ; Amisten S
Cell Physiol Biochem; 2018; 45(2):656-666. PubMed ID: 29408822
[TBL] [Abstract][Full Text] [Related]
9. Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression.
Koo T; Yoon AR; Cho HY; Bae S; Yun CO; Kim JS
Nucleic Acids Res; 2017 Jul; 45(13):7897-7908. PubMed ID: 28575452
[TBL] [Abstract][Full Text] [Related]
10. A carrier-free multiplexed gene editing system applicable for suspension cells.
Ju A; Lee SW; Lee YE; Han KC; Kim JC; Shin SC; Park HJ; EunKyeong Kim E; Hong S; Jang M
Biomaterials; 2019 Oct; 217():119298. PubMed ID: 31280073
[TBL] [Abstract][Full Text] [Related]
11. Reshaping Tumor Immune Microenvironment through Acidity-Responsive Nanoparticles Featured with CRISPR/Cas9-Mediated Programmed Death-Ligand 1 Attenuation and Chemotherapeutics-Induced Immunogenic Cell Death.
Tu K; Deng H; Kong L; Wang Y; Yang T; Hu Q; Hu M; Yang C; Zhang Z
ACS Appl Mater Interfaces; 2020 Apr; 12(14):16018-16030. PubMed ID: 32192326
[TBL] [Abstract][Full Text] [Related]
12. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
[TBL] [Abstract][Full Text] [Related]
13. New approaches to moderate CRISPR-Cas9 activity: Addressing issues of cellular uptake and endosomal escape.
van Hees M; Slott S; Hansen AH; Kim HS; Ji HP; Astakhova K
Mol Ther; 2022 Jan; 30(1):32-46. PubMed ID: 34091053
[TBL] [Abstract][Full Text] [Related]
14. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells.
Lin GL; Ting HJ; Tseng TC; Juang V; Lo YL
PLoS One; 2017; 12(10):e0185625. PubMed ID: 28968471
[TBL] [Abstract][Full Text] [Related]
16. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer.
Li M; Xie H; Liu Y; Xia C; Cun X; Long Y; Chen X; Deng M; Guo R; Zhang Z; He Q
J Control Release; 2019 Jun; 304():204-215. PubMed ID: 31100311
[TBL] [Abstract][Full Text] [Related]
18. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide.
Wang HX; Song Z; Lao YH; Xu X; Gong J; Cheng D; Chakraborty S; Park JS; Li M; Huang D; Yin L; Cheng J; Leong KW
Proc Natl Acad Sci U S A; 2018 May; 115(19):4903-4908. PubMed ID: 29686087
[TBL] [Abstract][Full Text] [Related]
19. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy.
Rosenblum D; Gutkin A; Kedmi R; Ramishetti S; Veiga N; Jacobi AM; Schubert MS; Friedmann-Morvinski D; Cohen ZR; Behlke MA; Lieberman J; Peer D
Sci Adv; 2020 Nov; 6(47):. PubMed ID: 33208369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
